聚乙二醇伊立替康治疗转移性乳腺癌伴脑转移患者:3期ATTAIN随机临床试验最终结果
ATTAIN是一项3期、开放标签、随机临床试验,在10个国家47个中心纳入178例有稳定经治脑转移的转移性乳腺癌患者,比较聚乙二醇伊立替康(145 mg/m2,每21天)与医生选择化疗的疗效。主要终点总生存两组相似(7.8 vs 7.5个月,HR 0.90,95%CI 0.61-1.33,P=0.60),未达统计学显著差异;安全性特征基本相当。
要点
- 聚乙二醇伊立替康组与化疗组中位OS分别为7.8个月和7.5个月,HR 0.90(95%CI 0.61-1.33,P=0.60)。
- 非中枢神经系统转移中位PFS两组为2.8 vs 1.9个月(HR 0.72,95%CI 0.45-1.16,P=0.18)。
- 中枢神经系统转移中位PFS两组为3.9 vs 3.3个月(HR 0.59,95%CI 0.33-1.05,P=0.07)。
核心结论
- ATTAIN试验结果显示,聚乙二醇伊立替康与化疗在脑转移患者中的结局无统计学显著差异。
- 该研究是专门针对乳腺癌伴脑转移患者发表的最大规模试验之一,可能有助于为进一步研究提供信息。
研究设计与样本
- 3期、开放标签、随机临床试验(ATTAIN),在10个国家47个中心开展。
- 纳入有稳定经治脑转移病史、在转移阶段化疗期间出现疾病进展的转移性乳腺癌患者,2017年3月7日至2019年11月6日入组。
- 共178例女性患者随机接受聚乙二醇伊立替康(92例,51.7%)或医生选择化疗(86例,48.3%)。
主要发现
- 聚乙二醇伊立替康组中位OS为7.8个月,化疗组为7.5个月(HR 0.90;95%CI 0.61-1.33;P=0.60)。
- 非中枢神经系统转移经盲法独立中心审查的中位PFS:聚乙二醇伊立替康组2.8个月 vs 化疗组1.9个月(HR 0.72;95%CI 0.45-1.16;P=0.18)。
- 中枢神经系统转移中位PFS:聚乙二醇伊立替康组3.9个月 vs 化疗组3.3个月(HR 0.59;95%CI 0.33-1.05;P=0.07)。
- 两组安全性特征基本相当。
关键数值与推荐
- 聚乙二醇伊立替康剂量为145 mg/m2,每21天给药一次。
- 化疗方案包括艾日布林、伊沙匹隆、长春瑞滨、吉西他滨、紫杉醇、多西他赛或白蛋白结合型紫杉醇。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the BEACON study did not meet its primary end point, treatment with etirinotecan pegol vs chemotherapy of the physician's choice for patients with advanced breast cancer demonstrated a significant improvement in overall survival (OS) for the prespecified patient subgroup with preexisting, pretreated, and nonprogressive BM. OBJECTIVE: To compare clinical outcomes in patients with BM treated with etirinotecan pegol vs chemotherapy of the physician's choice in a confirmatory trial. DESIGN, SETTING, AND PARTICIPANTS: This study was a phase 3, open-label, randomized clinical trial (ATTAIN) in patients with metastatic breast cancer and a history of stable pretreated BM who experienced disease progression while receiving chemotherapy in the metastatic setting. The trial took place at 47 sites in 10 countries, and patients were enrolled between March 7, 2017, and November 6, 2019. INTERVENTIONS: Patients were randomized to receive etirinotecan pegol, 145 mg/m2, every 21 days or chemotherapy (eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel). MAIN OUTCOMES AND MEASURES: The primary end point was OS. Key secondary end points included progression-free survival, objective response rate, duration of response, and the clinical benefit rate. RESULTS: A total of 178 female patients (9 [5.1%] Asian, 8 [4.5%] Black or African American, and 123 [69.1] White individuals) were randomized to receive treatment with etirinotecan pegol (92 [51.7%]; median [range] age, 53 [27-79] years) or chemotherapy (86 [48.3%]; median [range] age, 52 [24-77] years). Median OS was similar in both groups (etirinotecan pegol, 7.8 months; chemotherapy, 7.5 months; hazard ratio [HR], 0.90; 95% CI, 0.61-1.33; P = .60). Median progression-free survival for non-central nervous system metastases per blinded independent central review for etirinotecan pegol vs chemotherapy was 2.8 and 1.9 months (HR, 0.72; 95% CI, 0.45-1.16; P = .18) and 3.9 vs 3.3 months, respectively, for central nervous system metastases (HR, 0.59; 95% CI, 0.33-1.05; P = .07). Safety profiles between the groups were largely comparable. CONCLUSIONS AND RELEVANCE: The results of the ATTAIN randomized clinical trial found no statistically significant difference in outcomes between treatment with etirinotecan pegol and chemotherapy in patients with BM. However, this study represents one of the largest published trials dedicated to patients with breast cancer and BM and may help to inform further research. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02915744.
引用
- Tripathy D, Tolaney SM, Seidman AD, et al. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35552364. doi:10.1001/jamaoncol.2022.0514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。